Search
In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.
A new study has confirmed the changing pattern of meningococcal disease in Western Australia.
An international team of researchers has pioneered a technique which gives unprecedented insight into the dramatic changes occurring in a baby’s body in the first week of life.
As many as a quarter of Australian babies aren’t getting vaccinated on time, leaving them at risk of developing life-threatening illnesses such as whooping cough when they are most vulnerable.
New research investigating the devastating impact of the 2017 flu season by PAEDS-FluCAN, a national collaboration observing influenza in children, confirmed it was time to take action after thousands of children were hospitalised with the virus last year.
The eradication of rubella in Australia is evidence of the vital role vaccinations play in protecting our health, researchers at The Kids Research Institute Australia say.
The major funder of the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia has been recognised as Australia’s most generous giver.
Receiving vaccines at or close to their due date (vaccination timeliness) is a now key measure of program performance. However, studies comprehensively examining predictors of delayed infant vaccination are lacking. We aimed to identify predictors of short and longer-term delays in diphtheria-tetanus-pertussis (DTP) vaccination by dose number and ethnicity.
The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.
The main aim of the study is to provide timely surveillance data to public health authorities on severe influenza.